RTX was found to be non-inferior to daily CYC for the induction and maintenance of remission, but remission rates remain variable^11–13

• Patient achievement and maintenance of full remission remains variable with current therapies
• 1 in 3 patients fail to achieve remission at 6 months without use of GCs, and 1 in 2 fail to sustain remission at 12 months
• Non-severe relapse is an under-recognised clinical problem; these patients suffer subsequent relapses resulting in high GC exposure